Jiang Wenbin 4

What Happened Jiang Wenbin, President, CEO and a director of Cytek Biosciences (CTKB), had 4,514 restricted stock units (RSUs) convert into common shares on February 18, 2026. No cash was paid to convert these RSUs (conversion/exercise recorded at $0.00). To satisfy tax withholding obligations, 1,339 of the resulting shares were withheld and surrendered to the company at an indicated per-share value of $4.20, totaling $5,624.

Key Details

• Transaction date: February 18, 2026.
• Primary action: Conversion/exercise of 4,514 RSUs into common stock (derivative transaction code M).
• Tax withholding: 1,339 shares surrendered to issuer to cover withholding (code F) at $4.20/share = $5,624.
• Reported prices/values: Conversion recorded at $0.00 per share (no exercise price); tax withholding valued at $4.20/share.
• Shares owned after transaction: Not reported in the provided filing excerpt.
• Relevant footnotes: F1 = each RSU converts to one common share; F2 = withheld shares surrendered to issuer for taxes; F3 = RSUs vest quarterly over four years (vesting schedule described).
• Timeliness: No late filing indicated in the provided information.

Context This was not an open-market buy or sale but a routine RSU vesting and share-withholding to meet tax obligations (a cashless-style settlement). Such transactions reflect compensation vesting rather than a direct purchase or sale signal; they do not necessarily indicate insider buying or selling intent.